4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
SpyGlass Pharma, Inc. (SGP) operates in the Biotechnology industry and is headquartered in Aliso Viejo, United States with about 68 employees. Its market capitalization is roughly $669 million. In the fiscal year ended 2025-12-31, SGP reported $0M in revenue and ($40M) in net income.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Revenue | $0M | $0M | $0M |
| Operating Income (EBIT) | ($41M) | ($27M) | ($14M) |
| Net Income | ($40M) | ($29M) | ($13M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($15M) | ($14M) | ($7M) | ($8M) |
| Net Income | ($14M) | ($13M) | ($9M) | ($8M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Assets | $116M | $23M | $41M |
| Total Liabilities | $215M | $84M | $74M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SGP viewer.
About TickerBase · Data methodology & sources